Drugs / Dazucorilant
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT06928779 | Oct → Dec 2024 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT06495944 | May → Aug 2024 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04990310 | Aug → Sep 2021 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04994743 | Jul → Sep 2021 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04249323 | Jan → Oct 2020 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05407324 | Nov 2022 → Oct 2026 expected | amyotrophic lateral sclerosis | Corcept Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-04-30 | Corcept Therapeutics | Results Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis corcept.com ↗
today announced two-year overall survival data from the Phase 2 DAZALS study of its proprietary, selective cortisol modulator dazucorilant in patients with amyotrophic lateral sclerosis (ALS). |
| 2025-06-05 | Corcept Therapeutics | Results Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting corcept.com ↗
DAZALS did not meet its primary endpoint of improved outcome in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients who received dazucorilant compared to patients who received placebo |
| 2024-12-11 | Corcept Therapeutics | Results Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS) corcept.com ↗
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol, today announced results from the DAZALS study, a randomized, double-blind, placebo-controlled, Phase 2 trial evaluating two doses (150 mg and 300 mg) of its proprietary selective cortisol modulator dazucorilant in patients with ALS. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-30 | Corcept Therapeutics | Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis corcept.com ↗ |
| 2025-06-05 | Corcept Therapeutics | Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting corcept.com ↗ |
| 2024-12-11 | Corcept Therapeutics | Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS) corcept.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dazucorilant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06495944 ↗ |
| Known as | CORT113176 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04994743 ↗ |
| Modality | Small molecule | — CHEMBL3734774 ↗ |
| Route | Oral | “by mouth on Day 1” NCT04249323 ↗ |